Your Search Results

Imaging for structural heart disease intervention

19 Feb 2023 – From PCR Tokyo Valves 2023

Consult this session if you want to learn about imaging in structural heart interventions by exploring series of slides on restoration post transcatheter mitral valve repair, diagnostic performance of CT angiography, and AI in aortic complex measurement for TAVI, and more!

Other cardiac interventions

19 Feb 2023 – From PCR Tokyo Valves 2023

Explore innovative approaches to cardiac interventions featured at PCR Tokyo Valves 2023: from performing TricValve implantation in Asian patients to addressing unique cases like transcatheter valve replacement with a novel tricuspid bioprosthesis. Discover how these experts navigated challenging scenarios!

TAVI in patients with heavily calcified aortic root

19 Feb 2023 – From PCR Tokyo Valves 2023

What role does TAVI play in patients' severely calcified roots? Study the use of balloon-expandable devices, assessing the impact of calcification on aortic root rupture, strategies for safe and effective procedures, and when to consider surgical AVR.

Mitral valve implantation and other technology

19 Feb 2023 – From PCR Tokyo Valves 2023

This session offers insight into advanced mitral valve technologies. It covers details of transapical off-pump repair with synthetic chordae, India's success in transcatheter double valve-in-valve, TMVI in failing valves, and more.

Coronary access after TAVI

19 Feb 2023 – From PCR Tokyo Valves 2023

Unlock insights into post-TAVI coronary access. Understand transcatheter aortic valve structure, neo-commissure anatomy, and practical techniques. This session covers topics such as optimising commissure alignment, elective CAG/PCI, ACS, and severe aortic stenosis.

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author

Alessandro Sticchi

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

SMT’s Supraflex Cruz shows consistent and robust clinical outcomes across key global studies presented at TCT 2025

29 Oct 2025

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...